Eli Lilly Buys Startup CrossBridge Bio to Bring a More Powerful Strike to Tumors
Eli Lilly is paying as much as $300 million for CrossBridge Bio, a startup growing antibody drug conjugates that ship ...
Eli Lilly is paying as much as $300 million for CrossBridge Bio, a startup growing antibody drug conjugates that ship ...
Korsana Biosciences’ preclinical Alzheimer’s illness drug comes from a platform expertise that permits antibodies to cross the blood-brain barrier. Roche ...
The International Alzheimer’s Platform Basis® (GAP) is happy to welcome Spear Bio, a biotechnology firm pioneering wash-free ultrasensitive immunoassay know-how, ...
Eli Lilly is building its prospects in immunology through the $1.2 billion acquisition of Ventyx Biosciences, a clinical-stage company with ...
An experimental depression drug that joined the Neurocrine Biosciences pipeline as part of a broader package from Takeda Pharmaceutical failed ...
Colorectal cancer patients whose disease exhibits certain rare genetic signatures have the option of treatment with immunotherapies. But these targeted ...
How can a biotech startup raise more than $1 billion over four plus years and say almost nothing publicly along ...
Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT in 2021 ...
A clinical trial is typically the first look at how an experimental drug works in humans. Character Biosciences is entering ...
Bluebird Bio, a company that steered three gene therapies to FDA approval but struggled to commercialize them, has found the ...
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.